Analyst Expectations For Mirum Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
Mirum Pharmaceuticals (NASDAQ:MIRM) has been analyzed by five analysts, with ratings ranging from bullish to somewhat bullish. The average 12-month price target is $60.4, up 6.71% from the previous target. Analysts have raised their ratings and price targets, reflecting positive sentiment. Mirum's revenue growth and market capitalization are strong, but it faces challenges with debt management and return on equity.
October 11, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirum Pharmaceuticals has received positive analyst ratings, with an average price target increase to $60.4. Analysts have raised their ratings, indicating bullish sentiment. The company shows strong revenue growth but faces challenges in debt management.
The increase in average price target and positive analyst ratings suggest a bullish outlook for Mirum Pharmaceuticals. The company's strong revenue growth supports this sentiment, although high debt levels and low ROE present challenges. Overall, the positive analyst actions are likely to have a favorable short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100